JAMA Insights: Continuous Glucose Monitoring, published November 24, 2025. The image shows glucose monitoring data, including time in ranges, glucose metrics, ambulatory glucose profile (AGP), and daily glucose profiles.

Continuous glucose monitoring (CGM) enables real-time assessment of glucose trends in individuals with type 2 #diabetes, complementing or replacing fingerstick and HbA1c monitoring.

💡 This JAMA Insights discusses CGM use for type 2 diabetes.

ja.ma/4ogw8xz

Probably #nephsky will never see a trial comparing spironolactone with finerenone

Target emulated trial: potential benefits of finerenone in all sorts of outcomes, but we’re comparing 🔝methodology trials (FIGARO, FIDELIO) vs invetigator initiated trials

pubmed.ncbi.nlm.nih.gov/41173939/

Nephrotoxicity of Conventional Chemotherapeutics: Part I — Platinum Compounds and Antimetabolite Agents Abstract. Anticancer therapies have significantly improved survival rates in patients with cancer; however, despite prophylactic measures, many conventiona

Nephrotoxicity of Conventional Chemotherapeutics: Part I — Platinum Compounds and Antimetabolite Agents

doi.org/10.1093/ndt/...

Description of a prescription cascade, when an initial prescription for pregabalin or amlodipine causes leg oedema leading to addition of furosemide which causes urinary incontinence. This leads to a RX for Solifenacin which causes cognitive decline and a prescription for Don Pascale. The subsequent anorexia and an insomnia leads to mirtazapine prescription and a hip fracture from a fall. This of course leads to many other cascades, including delirium, haloperidol and levodopa, risedronate, and pantoprazole, or iron and constipation with peg.

From @carolyntan.bsky.social

This is a work of art

Have to agree that amlodipine and gabapentin/pregabalin often lead to heart failure misdiagnosis

#MedSky #PharmSky

h/t @davidjuurlink.bsky.social and @jbrianbyrd.bsky.social

It was a pleasure organizing our 5th course on Intensive Care Nephrology together with Nicole Bethke, Martin Kuhlmann and the Akademie Niere. Inspiring lectures and an outstanding group of participants! #nephsky #nephrology

The course is a great opportunity to learn about this important topic in its entirety, to expand your knowledge, and to broaden your horizons.

In three trials, finerenone reduced a range of cardiovascular and kidney outcomes in persons with diabetes and CKD.

Read more in #ASNJASN: kidney.pub/JASN0823

Graphic for the Nephrology 2025 annual meeting of the German Society of Nephrology. Text: ‘Progress in glomerulonephritis: more precise diagnoses, targeted innovative therapies and new guideline improve care.’ Below: ‘Nephrology 2025 – 17th Annual Meeting of the DGfN, October 2–5, 2025, Estrel Congress Center Berlin.’ Design in blue and green tones with logo.

More precise diagnoses, a new guideline and targeted therapies: Glomerulonephritis care is changing. Key topic at the DGfN Annual Meeting 2025 in Berlin.
Read more👉 bit.ly/4pwUxkc

#Nephrology #CKD

YouTube video by MARKUS at HOMe Post ESC 2025

It's Congress-Update time!
Check out our new webinar "Post ESC 2025"!

youtu.be/6C6lJWUHlc8?...

Visual abstract

How common is kidney failure with MCD and FSGS?

More than we think … @brianrifkin.bsky.social breaks down the recent @asnpublications.bsky.social JASN paper from the RaDaR study www.nephjc.com/news/nephjc-...

Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct effects of these drugs is the subject of intense interest. Although reductions in...

We propose that drug-induced weight loss is largely responsible for the reported improvements in osteoarthritis, obstructive sleep apnoea, and metabolic dysfunction-associated steatohepatitis outcomes www.thelancet.com/journals/lan...
#weightloss #GLP-1 receptor agonists

#MedSky #EndoSky#LiverSky

Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial Among patients receiving maintenance dialysis, spironolactone 25 mg daily orally did not reduce the composite outcome of cardiovascular mortality and hospitalisation due to heart failure compared with...

Spironolactone does not work for dialysis

ACHIEVE published in @thelancet.com

@lastwalsh.bsky.social and colleagues

www.thelancet.com/journals/lan...

Coming soon to a #NephJC near you

Peritoneal dialysis (PD) is not often used for patients with Autosomal dominant polycystic kidney disease (ADPKD). This #ASNKidney360 research demonstrates that PD is safe and effective for patients with ADPKD. Read more: kidney.pub/KID0888

Pregnancy-associated acute kidney injury — consensus report of the 32nd Acute Disease Quality Initiative workgroup Nature Reviews Nephrology, Published online: 18 July 2025; doi:10.1038/s41581-025-00979-6Pregnancy-associated acute kidney injury is a risk factor for maternal and fetal morbidity and mortality and a driver of health inequity worldwide. This Consensus Statement from the Acute Disease Quality Initiative provides recommendations on the causes, diagnosis, management and follow-up of pregnancy-associated acute kidney injury.

ICYMI:

Expanding the boundaries of kidney replacement therapy in patients with liver failure

CCR Journal Watch - tracking the critical care literature daily
https://criticalcarereviews.com/latest-evidence/journal-watch

The New England Journal of Medicine Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate A Research Summary based on Kahlmann V et al. | 10.1056/NEJMoa2501443 | Published on May 18, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.

In the PREDMETH trial, first-line treatment of pulmonary sarcoidosis with methotrexate was noninferior to that with prednisone regarding the change at 24 weeks in the percentage of the predicted forced vital capacity. Full trial results and Research Summary: nej.md/4kdaf0o

#MedSky #PulmSky

A new conceptual review for Secondary Membranous Nephropathy
Always think broader when the puzzle doesn’t fit perfectly.
#ECNeph @dramiliflores.bsky.social @karnephro.bsky.social
www.emjreviews.com/w...

Today's Paper of the Day is:

Demystifying Volume Status. An Ultrasound-Guided Physiologic Framework.

https://criticalcarereviews.com/latest-evidence/paper-of-the-day

Join us to read 1 paper per day and stay up-to-date as we cover the spectrum of critical care across 2025

Re-evaluating the concept of remission in type 2 diabetes: a call for patient-centric approaches Controlling weight and cardiovascular risk factors is paramount in type 2 diabetes management; however, the definition and feasibility of remission warrant closer examination. Type 2 diabetes remissio...

By re-evaluating current definitions, acknowledging the progressive nature of type 2 #diabetes, and embracing individualised approaches to glycaemic control, #remission can be redefined as a dynamic continuum rather than a static endpoint www.thelancet.com/journals/lan... #T2D

#MedSky #EndoSky

YouTube video by MARKUS at HOMe 62nd ERA Congress - Profs. L. Pyne, F. Fakhouri, M. Walsh, H. Mann, N. Staplin, V. Stel & J. Barratt

Best of ERA 25 @markusathome.bsky.social with
@lonniepyne.bsky.social @lastwalsh.bsky.social
Dr. Stel Dr. Staplin Dr. Mann Dr. Fakhouri
@rosertorra.bsky.social @katestevens.bsky.social @marcussaemann.bsky.social @sarahelena.bsky.social
@dgfn.bsky.social @sfndt.bsky.social
youtu.be/HbUEh8oLB2M?...

YouTube video by MARKUS at HOMe Post ERA 2025 - NDT / MARKUS at HOMe Special

Post-ERA 2025 webinar on 13 June at 7:15 pm! Late-Breaker on kidney diseases in focus - with top researchers, including on IgAN, C3G, MRA & transplantation. Make a note now!
👉MARKUS at HOMe: www.youtube.com/watch?v=Q6WP...

YouTube video by MARKUS at HOMe Post ERA 2025 - NDT / MARKUS at HOMe Special

youtu.be/s-iglqVIp2s?...

With @marcussaemann.bsky.social @sarahelena.bsky.social @rosertorra.bsky.social Prof. Anders Prof. Stevens

In the CONFIDENCE trial, combo therapy with #finerenone + #empagliflozin led to a >50% reduction in albuminuria over 180 days in patients with #CKD & #T2D — significantly greater than either drug alone. Safe, effective, synergistic.
👉 www.nejm.org/doi/full/10....

🔍 New meta-analysis of 1.8M+ patients shows even mild or short-duration AKI significantly increases risk of CKD, kidney failure & MAKE.
➡️ AKI stage 1: HR 1.49 for CKD
➡️ AKI <3 days: OR 2.37 for CKD
📢 Time to prioritize post-AKI kidney protection!

doi.org/10.1093/ndt/...

YouTube video by MARKUS at HOMe Update Nierentransplantation 2025 - Prof. Dr. Georg Böhmig (Wien, Österreich)

It's time for a new update on kidney transplantation with Prof. Böhmig!

youtu.be/qlgBwc6g4rQ?...

Increased nighttime SBP is a more critical factor than hyperglycemia in affecting retinal vascular caliber changes in newly diagnosed T2DM patients

🔗 academic.oup.com/ajh/article/... 🔒

Inflammatory and Cardiovascular Events in CKD: The Multi-Ethnic Study of Atherosclerosis

bit.ly/Shroff25OI

@alexchangmd.bsky.social‬ #CKD #VisualAbstract

This Core Curriculum by Kevin Bryan et al explores commonly implicated pathophysiological mechanisms in kidney dysfunction in heart failure and discuss the principles behind effective decongestion and assessment of adequacy of natriuresis:

bit.ly/434spfa (FREE)

Long-term risks of adverse kidney outcomes after acute kidney injury: a systematic review and meta-analysis

doi.org/10.1093/ndt/...